Healthcare Jul 29, 2021 08:18 AM (GMT+8) · EqualOcean
On the 29th, yiouda health learned that industrial synthetic biotechnology company bota Biosciences (hereinafter referred to as "bota bio") announced that it had completed a round B financing of more than US $100 million, which was led by Sequoia China, followed by CMB international capital and front wheel investors Jingwei China, Sherpa investment, source capital, five source capital, meituan, etc. So far, the total financing of bota bio has exceeded US $145 million, setting a record in the financing speed and scale in the field of synthetic biology in Asia. Founded in 2019, bota bio is a biotechnology company based on the concept of synthetic biology. By creating a standardized and automated high-throughput experimental operation platform, combined with machine learning and artificial intelligence, bota bio carries out systematic engineering editing of organisms, and develops high-efficiency, green and low-cost industrial biotechnology suitable for large-scale production for chemical industry, food Provide key technical solutions for agriculture, pharmaceutical and other industries. At present, it has initially built a highly integrated automation technology platform, bota freeway, which can promote the parallel research and development of multiple product pipelines at high speed. The financing will be used to expand the company's global business and further improve the construction of bota freeway, high-precision fermentation platform and pilot base, so as to promote the further expansion of the company's product pipeline in the fields of consumer goods, food, nutrition and medicine.